Head-to-head evidence
177Lu-DWJ155 vs Disitamab Vedotin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: HER2 · full Non-Small Cell Lung Cancer pipeline
177Lu-DWJ155
Developed by Novartis
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: May 2032 · NCT07660055 (registry estimate)
Disitamab Vedotin
Developed by RemeGen Co., Ltd.
NCT04311034 · Phase 1/2 · completed
The study was an uncontrolled, open-label single-arm trial of 37 participants, so it could not compare disitamab vedotin with placebo or another treatment. Its primary outcomes were clinical tumor measures, but the primary endpoint result has not been reported.
Next expected readout: June 2027 · NCT06734182 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: 177Lu-DWJ155's landscape · Disitamab Vedotin's landscape